Magenta Therapeutics Inc ASH 2019 Transcript
All right, everyone. Welcome. Thank you for joining our event in glamorous Orlando. We're happy to see you all here. I'm Manisha Pai, I am our Vice President of Investor Relations and Communications at Magenta.
Before we begin, I'd like to remind you that we will be making forward-looking statements. There are risks associated with investing in Magenta, and I encourage you to read our filings with the SEC.
So we've got a great agenda for you guys tonight. First, our CEO, Jason Gardner, will kick off with just a brief overview of Magenta as a company and our vision; followed by David Scadden, who is one of our co-founders as well as a Professor of Medicine at Harvard and the Harvard Stem Cell Institute, and he's going to be talking about some landmark results for conditioning -- alternative conditioning for gene therapy, and we're really excited about these results. He'll be followed by Dr. John DiPersio of Washington University in St. Louis, who'll be walking through the initial Phase I results for our MGTA-145 stem
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |